These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

742 related items for PubMed ID: 32493676

  • 1. The Use of Multiparametric Magnetic Resonance Imaging for Follow-up of Patients Included in Active Surveillance Protocol. Can PSA Density Discriminate Patients at Different Risk of Reclassification?
    Roscigno M, Stabile A, Lughezzani G, Pepe P, Galosi AB, Naselli A, Naspro R, Nicolai M, La Croce G, Aljoulani M, Perugini G, Guazzoni G, Montorsi F, Balzarini L, Sironi S, Da Pozzo LF.
    Clin Genitourin Cancer; 2020 Dec; 18(6):e698-e704. PubMed ID: 32493676
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Multiparametric magnetic resonance imaging and clinical variables: Which is the best combination to predict reclassification in active surveillance patients?
    Roscigno M, Stabile A, Lughezzani G, Pepe P, Dell'Atti L, Naselli A, Naspro R, Nicolai M, La Croce G, Muhannad A, Perugini G, Guazzoni G, Montorsi F, Balzarini L, Sironi S, Da Pozzo LF.
    Prostate Int; 2020 Dec; 8(4):167-172. PubMed ID: 33425794
    [Abstract] [Full Text] [Related]

  • 4. Added Value of Prostate-specific Antigen Density in Selecting Prostate Biopsy Candidates Among Men with Elevated Prostate-specific Antigen and PI-RADS ≥3 Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate: A Systematic Assessment by PI-RADS Score.
    Pellegrino F, Stabile A, Sorce G, Quarta L, Robesti D, Cannoletta D, Cirulli G, Barletta F, Scuderi S, Mazzone E, de Angelis M, Brembilla G, De Cobelli F, Salonia A, Montorsi F, Briganti A, Gandaglia G.
    Eur Urol Focus; 2024 Jul; 10(4):634-640. PubMed ID: 37865591
    [Abstract] [Full Text] [Related]

  • 5. Single center analysis of an advisable control interval for follow-up of patients with PI-RADS category 3 in multiparametric MRI of the prostate.
    Boschheidgen M, Schimmöller L, Doerfler S, Al-Monajjed R, Morawitz J, Ziayee F, Mally D, Quentin M, Arsov C, Albers P, Antoch G, Ullrich T.
    Sci Rep; 2022 Apr 25; 12(1):6746. PubMed ID: 35469056
    [Abstract] [Full Text] [Related]

  • 6. Clinical utility of MR/ultrasound fusion-guided biopsy in patients with lower suspicion lesions on active surveillance for low-risk prostate cancer.
    Lokeshwar SD, Nguyen J, Rahman SN, Khajir G, Ho R, Ghabili K, Leapman MS, Weinreb JC, Sprenkle PC.
    Urol Oncol; 2022 Sep 25; 40(9):407.e21-407.e27. PubMed ID: 35811206
    [Abstract] [Full Text] [Related]

  • 7. Risk-Adapted Strategy Combining Magnetic Resonance Imaging and Prostate-Specific Antigen Density to Individualize Biopsy Decision in Patients With PI-RADS 3 ``Gray Zone'' Lesions.
    Akpinar C, Oz DK, Oktar A, Suer E, Ozden E, Haliloglu N, Gulpinar O, Gokce MI, Gogus C, Baltaci S.
    Clin Genitourin Cancer; 2024 Jun 25; 22(3):102071. PubMed ID: 38555682
    [Abstract] [Full Text] [Related]

  • 8. Characterizing indeterminate (Likert-score 3/5) peripheral zone prostate lesions with PSA density, PI-RADS scoring and qualitative descriptors on multiparametric MRI.
    Brizmohun Appayya M, Sidhu HS, Dikaios N, Johnston EW, Simmons LA, Freeman A, Kirkham AP, Ahmed HU, Punwani S.
    Br J Radiol; 2018 Feb 25; 91(1083):20170645. PubMed ID: 29189042
    [Abstract] [Full Text] [Related]

  • 9. Unified model involving genomics, magnetic resonance imaging and prostate-specific antigen density outperforms individual co-variables at predicting biopsy upgrading in patients on active surveillance for low risk prostate cancer.
    Beksac AT, Ratnani P, Dovey Z, Parekh S, Falagario U, Roshandel R, Sobotka S, Kewlani D, Davis A, Weil R, Bashorun H, Jambor I, Lewis S, Haines K, Tewari AK.
    Cancer Rep (Hoboken); 2022 Mar 25; 5(3):e1492. PubMed ID: 34931468
    [Abstract] [Full Text] [Related]

  • 10. Comparison of different thresholds of PSA density for risk stratification of PI-RADSv2.1 categories on prostate MRI.
    Girometti R, Giannarini G, Panebianco V, Maresca S, Cereser L, De Martino M, Pizzolitto S, Pecoraro M, Ficarra V, Zuiani C, Valotto C.
    Br J Radiol; 2022 Mar 01; 95(1131):20210886. PubMed ID: 34762506
    [Abstract] [Full Text] [Related]

  • 11. Combining clinical parameters and multiparametric magnetic resonance imaging to stratify biopsy-naïve men for an optimum diagnostic strategy with prostate-specific antigen 4 ng ml-1 to 10 ng ml-1.
    Zhang CC, Tu X, Lin TH, Cai DM, Yang L, Qiu S, Liu ZH, Yang L, Wei Q.
    Asian J Androl; 2023 Mar 01; 25(4):492-498. PubMed ID: 36571328
    [Abstract] [Full Text] [Related]

  • 12. MRI combined with PSA density in detecting clinically significant prostate cancer in patients with PSA serum levels of 4∼10ng/mL: Biparametric versus multiparametric MRI.
    Han C, Liu S, Qin XB, Ma S, Zhu LN, Wang XY.
    Diagn Interv Imaging; 2020 Apr 01; 101(4):235-244. PubMed ID: 32063483
    [Abstract] [Full Text] [Related]

  • 13. Who with suspected prostate cancer can benefit from Proclarix after multiparametric magnetic resonance imaging?
    Morote J, Campistol M, Regis L, Celma A, de Torres I, Semidey ME, Roche S, Mast R, Santamaria A, Planas J, Trilla E.
    Int J Biol Markers; 2022 Jun 01; 37(2):218-223. PubMed ID: 35200058
    [Abstract] [Full Text] [Related]

  • 14. Multiparametric magnetic resonance imaging facilitates reclassification during active surveillance for prostate cancer.
    Fujihara A, Iwata T, Shakir A, Tafuri A, Cacciamani GE, Gill K, Ashrafi A, Ukimura O, Desai M, Duddalwar V, Stern MS, Aron M, Palmer SL, Gill IS, Abreu AL.
    BJU Int; 2021 Jun 01; 127(6):712-721. PubMed ID: 33043575
    [Abstract] [Full Text] [Related]

  • 15. Avoiding Unnecessary Magnetic Resonance Imaging (MRI) and Biopsies: Negative and Positive Predictive Value of MRI According to Prostate-specific Antigen Density, 4Kscore and Risk Calculators.
    Falagario UG, Martini A, Wajswol E, Treacy PJ, Ratnani P, Jambor I, Anastos H, Lewis S, Haines K, Cormio L, Carrieri G, Rastinehad AR, Wiklund P, Tewari A.
    Eur Urol Oncol; 2020 Oct 01; 3(5):700-704. PubMed ID: 31548130
    [Abstract] [Full Text] [Related]

  • 16. Diagnostic Accuracy of Single-plane Biparametric and Multiparametric Magnetic Resonance Imaging in Prostate Cancer: A Randomized Noninferiority Trial in Biopsy-naïve Men.
    Russo F, Mazzetti S, Regge D, Ambrosini I, Giannini V, Manfredi M, De Luca S, Bollito E, Porpiglia F.
    Eur Urol Oncol; 2021 Dec 01; 4(6):855-862. PubMed ID: 33893066
    [Abstract] [Full Text] [Related]

  • 17. Negative multiparametric magnetic resonance imaging for prostate cancer: further outcome and consequences.
    Haack M, Miksch V, Tian Z, Duwe G, Thomas A, Borkowetz A, Stroh K, Thomas C, Haferkamp A, Höfner T, Boehm K.
    World J Urol; 2022 Dec 01; 40(12):2947-2954. PubMed ID: 36318314
    [Abstract] [Full Text] [Related]

  • 18. PSA density is complementary to prostate MP-MRI PI-RADS scoring system for risk stratification of clinically significant prostate cancer.
    Frisbie JW, Van Besien AJ, Lee A, Xu L, Wang S, Choksi A, Afzal MA, Naslund MJ, Lane B, Wong J, Wnorowski A, Siddiqui MM.
    Prostate Cancer Prostatic Dis; 2023 Jun 01; 26(2):347-352. PubMed ID: 35523940
    [Abstract] [Full Text] [Related]

  • 19. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
    Zhang Y, Zeng N, Zhang F, Huang Y, Tian Y.
    Int J Clin Oncol; 2020 Jan 01; 25(1):175-186. PubMed ID: 31473884
    [Abstract] [Full Text] [Related]

  • 20. Outcomes of Serial Multiparametric Magnetic Resonance Imaging and Subsequent Biopsy in Men with Low-risk Prostate Cancer Managed with Active Surveillance.
    Hsiang W, Ghabili K, Syed JS, Holder J, Nguyen KA, Suarez-Sarmiento A, Huber S, Leapman MS, Sprenkle PC.
    Eur Urol Focus; 2021 Jan 01; 7(1):47-54. PubMed ID: 31147263
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.